Conditioning regimen for stem cell transplant in older adults with AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a special combination of chemotherapy drugs (called a conditioning regimen) given before a half-matched stem cell transplant for older adults with acute myeloid leukemia (AML) in their first remission. The goal is to make the transplant safer and more effective for people aged 55 to 75.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 55 and 75 years old.
- You have acute myeloid leukemia (AML) and are in your first complete remission (or a similar state with incomplete blood count recovery).
- You have a half-matched (haploidentical) donor, such as a parent, child, or sibling, who can donate stem cells.
- You are in generally good health (able to carry out daily activities) and your heart, lungs, liver, and kidneys are working well enough for a transplant.
- You are not pregnant or breastfeeding, and you do not have HIV, active hepatitis B or C, or an uncontrolled infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gentler chemotherapy regimen (fludarabine and treosulfan) before a stem cell transplant from a half-matched donor. It aims to make the transplant safer and more effective for older or frailer patients with acute myeloid leukemia.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This trial tests a less intense chemotherapy and radiation combination (called TMLI, fludarabine, and melphalan) before a stem cell transplant from a matched donor. The goal is to help prepare your body for the transplant while reducing side effects, so it may be a good option if you have high-risk MDS or AML and cannot tolerate the standard, more intensive conditioning regimen.
This trial tests a stem cell transplant using a half-matched donor, followed by extra immune cells and targeted drugs, for people with acute myeloid leukemia (AML) that is still active or has come back. The goal is to try to control the leukemia and improve outcomes.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This trial tests a combination of two chemotherapy drugs given before a stem cell transplant to help people with acute myeloid leukemia (AML) that has not responded to treatment or has come back. The goal is to improve the success of the transplant.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.